ExiPrep™ cfDNA Extraction Kit is designed for accurate and rapid extraction of cell-free DNA from various samples such as serum, urine and saliva using Exiprep 96 Lite. ExiPrep™ 96 cfDNA Kit contains all buffers and consumables already prefilled in cartridges for easy load into Exiprep 96 automated Nucleic Extraction instrument. This kit uses our exclusive nano sized magnetic bead which allows easier isolation and purification of cell-free DNA from body fluid.
Once loaded, 24 samples are processed in only 35 minutes!
Features and Benefits
- Pre-filled buffer cartridge system.
- A broad range of cell-free DNA extraction from samples such as plasma, serum, urine, saliva, etc.
- Elution volume is adjustable based on needs.
- Uses silica magnetic nano beads for more surface area coverage for more efficient extraction and DNA recovery
Specifications
| Target | cfDNA |
|---|
| Specimen | Plasma, Serum, Urine, Saliva |
|---|
| Starting volume | 1 - 4 ml |
|---|
| Elution volume | 20 - 100 ul |
|---|
| Instrumention | ExiPrep™ 96 Lite |
|---|
| Test | 96 tests (4 x 24-well plates) |
|---|
| Turnaround time | 35 minutes |
|---|
Workflow
Applications
- PCR
- Real-time PCR
- Sanger Sequencing
- Pyro Sequencing
- Next-generation sequencing (NGS)
- Bisulfite conversion
Downstream application of cfDNA
- Cancer diagnosis
The fraction of cfDNA released by tumor cells in circulation is in uenced by the size of the tumor as well as the tumor stage and type.
- Detection of cancer: localization, origin, stage
- Early detection (early and late stage)
- Monitoring of cancer therapy
- Assays for clinical use
- Liquid biopsy
cfDNA allows a rapid, easy, non-invasive and repetitive method of sampling. The technical merit of sampling makes cfDNA a potential biomarker for liquid biopsy.
- Immune diseases
- Sepsis
- Myocardial Infarction, etc.
- NIPT
Non-Invasive Prenatal Test (NIPT) analyzes cfDNA from a maternal blood sample to screen for common chromosomal conditions in the fetus.
- Organ transplantation
Foreign cfDNA is present in the plasma of solid organ transplant patients, which is derived from the grafted organ and is termed dd-cfDNA (donor-derived cell-free DNA). It can be used for the detection of transplant rejection.